keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28812136/clinical-outcomes-of-y90-radioembolization-for-recurrent-hepatocellular-carcinoma-following-curative-resection
#1
Rehan Ali, Ahsun Riaz, Ahmed Gabr, Nadine Abouchaleh, Ronald Mora, Ali Al Asadi, Juan Carlos Caicedo, Michael Abecassis, Nitin Katariya, Haripriya Maddur, Laura Kulik, Robert J Lewandowski, Riad Salem
PURPOSE: To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. METHODS: With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed...
August 15, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28792803/transarterial-radioembolization-for-hepatocellular-carcinoma-is-safe-but-is-it-effective
#2
Alain Braillon
No abstract text is available yet for this article.
June 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28767473/acquired-hemophilia-a-after-hepatic-yttrium-90-radioembolization-a-case-report
#3
Susanna Tribuzi, Alessia Naccarato, Lorella Pelagalli, Marco Covotta, Giulia Torregiani, Claudia Claroni, Ester Forastiere
Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by the development of autoantibodies (inhibitors) directed against plasma coagulation factors, most frequently factor VIII. We report a case of a 65-year-old man with hepatocellular carcinoma who bled massively after a hepatic Yttrium-90 radioembolization procedure (Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres [SIRTex]). An acquired deficiency of factor VIII was diagnosed and successfully treated with recombinant activated factor VII and immunosuppression...
August 1, 2017: A & A Case Reports
https://www.readbyqxmd.com/read/28758319/treatment-options-for-unresectable-hcc-with-a-focus-on-sirt-with-yttrium-90-resin-microspheres
#4
REVIEW
Eric A Wang, Jeff P Stein, Ross J Bellavia, Scott R Broadwell
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, is the second leading cause of cancer-related deaths across the globe. Only a small percentage of HCC patients (~20%-30%) are diagnosed at an early stage when first-line treatment options may be effective. The majority of HCC patients (>70%) are diagnosed with unresectable disease and given a poor overall prognosis. Current treatment guidelines recommend locoregional therapy with transarterial chemoembolisation (TACE) and systemic therapy with sorafenib as first-line treatment for patients with intermediate and advanced stage HCC...
July 30, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28736826/impact-of-respiratory-motion-and-acquisition-settings-on-spect-liver-dosimetry-for-radioembolization
#5
Remco Bastiaannet, Max A Viergever, Hugo W A M de Jong
PURPOSE: Respiratory motion may impose significant inaccuracies on emission activity estimation in quantitative SPECT. This effect may be a major issue in dosimetry as used in management of liver radioembolization. The purpose of this study was to investigate the impact of respiratory motion on radioembolization liver dosimetry for different SPECT acquisition settings. METHODS: In a series of SPECT/CT Monte Carlo simulations using several digital XCAT phantoms, the following parameters were varied: breathing/non-breathing, liver tumor size (0...
July 24, 2017: Medical Physics
https://www.readbyqxmd.com/read/28726679/accuracy-of-rhenium-188-spect-ct-activity-quantification-for-applications-in-radionuclide-therapy-using-clinical-reconstruction-methods
#6
Pedro L Esquinas, Carlos F Uribe, M Gonzalez, Cristina Rodríguez-Rodríguez, Urs O Häfeli, Anna Celler
The main applications of (188)Re in radionuclide therapies include trans-arterial liver radioembolization and palliation of painful bone-metastases. In order to optimize (188)Re therapies, the accurate determination of radiation dose delivered to tumors and organs at risk is required. Single photon emission computed tomography (SPECT) can be used to perform such dosimetry calculations. However, the accuracy of dosimetry estimates strongly depends on the accuracy of activity quantification in (188)Re images...
July 20, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28725431/angiosarcoma-treated-successfully-with-anti-pd-1-therapy-a-case-report
#7
Simran Sindhu, Lana H Gimber, Lee Cranmer, Ali McBride, Andrew S Kraft
BACKGROUND: Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patients; with the cutaneous form most common in older white men. Combined modality therapy including surgery and radiation appears to have a better outcome than each modality alone. When metastatic, agents such as liposomal doxorubicin, paclitaxel and ifosfamide have activity but it is short-lived and not curative...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28716069/angiosarcoma-treated-successfully-with-anti-pd-1-therapy-a-case-report
#8
Simran Sindhu, Lana H Gimber, Lee Cranmer, Ali McBride, Andrew S Kraft
BACKGROUND: Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patients; with the cutaneous form most common in older white men. Combined modality therapy including surgery and radiation appears to have a better outcome than each modality alone. When metastatic, agents such as liposomal doxorubicin, paclitaxel and ifosfamide have activity but it is short-lived and not curative...
July 18, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28708902/factors-associated-with-contralateral-liver-hypertrophy-after-unilateral-radioembolization-for-hepatocellular-carcinoma
#9
Juliane Goebel, Maximilian Sulke, Andrea Lazik-Palm, Thomas Goebel, Alexander Dechêne, Alexander Bellendorf, Stefan Mueller, Lale Umutlu, Jens Theysohn
INTRODUCTION: Radioembolization for the treatment of hepatocellular carcinoma (HCC) induces liver volume changes referred to as "atrophy-hypertrophy complex". The aim of this study was to investigate lobar liver volume changes after unilateral radioembolization and to search for factors associated with hypertrophy of the untreated lobe. MATERIALS AND METHODS: Seventy-five patients were retrospectively evaluated. Inclusion criteria were: (1) right-lobar radioembolization for unresectable unilateral HCC, (2) available liver computed tomography scans before, 1, 3, and at least 6 months after radioembolization...
2017: PloS One
https://www.readbyqxmd.com/read/28689934/single-center-comparison-of-overall-survival-and-toxicities-in-patients-with-infiltrative-hepatocellular-carcinoma-treated-with-yttrium-90-radioembolization-or-drug-eluting-embolic-transarterial-chemoembolization
#10
Joseph L McDevitt, Ali Alian, Baljendra Kapoor, Stacy Bennett, Amanjit Gill, Abraham Levitin, Mark Sands, K V Narayanan Menon, Federico N Aucejo, Bassam Estfan, Anil K Pillai, Sanjeeva P Kalva, Gordon McLennan
PURPOSE: To compare overall survival and toxicities after yttrium-90 ((90)Y) radioembolization and chemoembolization with drug-eluting embolics (DEE) in patients with infiltrative hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Retrospective review of 50 patients with infiltrative HCC without main portal vein invasion who were treated with (90)Y radioembolization (n = 26) or DEE chemoembolization (n = 24) between March 2007 and August 2012 was completed...
July 6, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28686171/systematic-investigation-on-the-validity-of-partition-model-dosimetry-for-sup-90-sup-y-radioembolization-using-monte-carlo-simulation
#11
Nurul Ab Aziz Hashikin, Chai-Hong Yeong, Susanna Guatelli, Basri Johan Jeet Abdullah, Kwan-Hoong Ng, Alessandra Malaroda, Anatoly B Rozenfeld, Alan C Perkins
We aimed to investigate the validity of the partition model (PM) in estimating the absorbed doses to liver tumour (D<sub>T</sub>), normal liver tissue (D<sub>NL</sub>) and lungs (D<sub>L</sub>), when cross-fire irradiations between these compartments are being considered. Methods: MIRD-5 phantom incorporated with various treatment parameters, i.e. tumour involvement (TI), tumour-to-normal liver uptake ratio (T/N) and lung shunting (LS), were simulated using the Geant4 Monte Carlo (MC) toolkit...
July 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28682846/punctate-radiation-dermatitis-of-the-foot-and-ankle-caused-by-distal-embolization-of-90y-microspheres-during-liver-directed-therapy
#12
Benjamin B Nia, Emily S Nia, Ryan J Avery, Phillip H Kuo, Charles T Hennemeyer
A 41-year-old man with gastric adenocarcinoma presented with hepatic metastases. The metastases were refractory to systemic chemotherapy, so radioembolization with Y microspheres was performed. Because of stasis or saturation of the tumor with embolic particles, 79% of the microspheres were injected. At follow-up, the patient complained of "red bumps" that had developed on his right foot/ankle the day after the radioembolization. Because a portion of the dose was still in the catheter when withdrawn from the right femoral artery, the interventional radiologist used a Geiger counter to confirm radioactivity in the cutaneous lesions and thus the distal embolization of the microspheres...
September 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28673658/long-term-hepatotoxicity-of-yttrium-90-radioembolization-as-treatment-of-metastatic-neuroendocrine-tumor-to%C3%A2-the%C3%A2-liver
#13
Yu-Kai Su, Rosewell V Mackey, Ahsun Riaz, Vanessa L Gates, Al B Benson, Frank H Miller, Vahid Yaghmai, Ahmed Gabr, Riad Salem, Robert J Lewandowski
PURPOSE: To determine long-term hepatotoxicity of yttrium-90 ((90)Y) radioembolization in patients treated for metastatic neuroendocrine tumor (mNET) and evaluate if imaging and laboratory findings of cirrhosis-like morphology are associated with clinical symptoms. MATERIALS AND METHODS: Retrospective review from 2003 to 2016 was performed for patients with mNET treated with (90)Y glass microspheres. Fifty-four patients with > 2 year follow-up were stratified into unilobar (n = 15) vs whole-liver (n = 39) treatment...
June 30, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28668402/comparative-study-of-post-transplant-outcomes-in-hepatocellular-carcinoma-patients-treated-with-chemoembolization-or-radioembolization
#14
Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Michael Vouche, Rohi Atassi, Khairuddin Memon, Ali Al Asadi, Talia Baker, Juan Carlos Caicedo, Kush Desai, Jonathan Fryer, Ryan Hickey, Michael Abeccassis, Ali Habib, Elias Hohlastos, Daniel Ganger, Laura Kulik, Robert J Lewandowski, Ahsun Riaz, Riad Salem
PURPOSE: To analyze long-term outcomes in patients bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 radioembolization (Y90) for hepatocellular carcinoma (HCC). METHODS: 172 HCC patients who underwent OLT after being treated with transarterial liver-directed therapies (LDTs) (Y90: 93; TACE: 79) were identified. Pre-LDT and pre-OLT clinical/imaging/laboratory characteristics including United Network for Organ Sharing (UNOS) staging and alpha-fetoprotein values (AFP) were tabulated...
August 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#15
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28643305/-interventional-therapy-of-colorectal-liver-metastasis
#16
Qi Zhang, Gaojun Teng
Colorectal liver metastasis (CRLM) is one of the most difficult and key points in the treatment of colorectal cancer. Approximately 50% to 60% of patients diagnosed as colorectal cancer develops metastasis, and 80% to 90% of CRLM is unresectable. Surgical resection is the first-line treatment for CRLM, while it is only suitable for about 15% patients. Systemic chemotherapy can prolong the survival of CRLM patients, however, a part of CRLM patients are resistant to chemotherapy. With the development of technology and the update of clinical evidence, individual therapy with target drugs and multidisciplinary treatment (MDT) have became a tendency, and minimally invasive interventional therapy has gained more acceptance in the MDT mode of the treatment for CRLM...
June 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28624008/a-systematic-review-of-yttrium-90-radioembolization-for-unresectable-liver-metastases-of-melanoma
#17
REVIEW
Zhongzhi Jia, Guomin Jiang, Chunfu Zhu, Kai Wang, Shaoqin Li, Xihu Qin
PURPOSE: To assess the effectiveness of yttrium-90 ((90)Y) radioembolization in the treatment of unresectable liver metastases of melanoma. METHODS: PubMed and EMBASE were systemically searched for all English language studies related to (90)Y radioembolization for unresectable liver metastases of melanoma, including clinical trials, observational studies, and abstracts from conferences, published between January 1991 and March 2016. RESULTS: A total of 12 reports (7 observational studies and 5 abstracts from conferences) involving 255 patients were included in the analysis...
July 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28608276/a-comparison-of-yttrium-90-microsphere-radioembolization-to-hepatic-arterial-infusional-chemotherapy-for-patients-with-chemo-refractory-hepatic-colorectal-metastases
#18
REVIEW
Andrea Cercek, Vyacheslav Gendel, Salma Jabbour, Dirk Moore, Chunxia Chen, John Nosher, Marinela Capanu, Joanne F Chou, Taryn Boucher, Nancy Kemeny, Darren R Carpizo
Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90...
July 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28605614/medical-management-of-hepatocellular-carcinoma
#19
Nicole E Rich, Adam C Yopp, Amit G Singal
Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so therapeutic decisions must account for the degree of underlying liver dysfunction and patient performance status in addition to tumor burden. Curative treatment options, including liver transplantation, surgical resection, and local ablative therapies, offer 5-year survival rates exceeding 60% but are restricted to patients with early-stage HCC. Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28598685/radioembolization-for-unresectable-intrahepatic-cholangiocarcinoma-review-of-safety-response-evaluation-criteria-in-solid-tumors-1-1-imaging-response-and-survival
#20
Nathaniel C Swinburne, Derek M Biederman, Cecilia Besa, Nora E Tabori, Aaron M Fischman, Rahul S Patel, Francis Scott Nowakowski, Ganesh Gunasekaran, Myron E Schwartz, Robert A Lookstein, Edward Kim
The optimal palliative treatment for unresectable intrahepatic cholangiocarcinoma (ICC) remains controversial. While selective internal radiation therapy (SIRT) using yttrium-90 microspheres is a well-accepted treatment for hepatocellular carcinoma, data related to its use for locally advanced ICC remain relatively scarce. Twenty-nine patients (mean age 66 ± 11 years; 15 female) with unresectable biopsy-proven ICC treated with SIRT between June 2008 and April 2015 were retrospectively evaluated for post-treatment toxicity, overall survival, and imaging response using response evaluation criteria in solid tumors (RECIST) 1...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"